Product image of Golpimec (Fingolimod) supplied by GNH India

Golpimec

Active Ingredient:
Fingolimod
Origin:
EU

Golpimec (Fingolimod)

Golpimec is an oral medication whose active ingredient is fingolimod. It is classified as a sphingosine‑1‑phosphate receptor modulator and is marketed in the European Union as a prescription‑only disease‑modifying therapy for multiple sclerosis. The product is taken by mouth and is intended for patients with relapsing forms of the disease.

Manufacturer / TM Owner

Neuraxpharm Sweden Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Golpimec is prescribed to modify disease activity in patients with multiple sclerosis. It is used as part of a comprehensive treatment plan for relapsing‑remitting and active secondary progressive forms of the condition.

  • Reduces the frequency of clinical relapses.
  • Slows accumulation of disability over time.
  • May decrease new or enlarging MRI lesions.
  • Used when first‑line therapies are insufficient or not tolerated.
  • Often combined with regular neurologic monitoring.

Side Effects

Side effects of Golpimec vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

  • Headache
  • Diarrhea
  • Upper respiratory tract infection
  • Elevated liver enzymes
  • Fatigue
  • Nasopharyngitis

Serious

  • Infections such as herpes zoster
  • Cardiac conduction abnormalities (e.g., bradycardia)
  • Macular edema
  • Severe liver injury
  • Progressive multifocal leukoencephalopathy (PML)
  • Respiratory complications

Precautions & Warnings

Before starting Golpimec, clinicians evaluate several safety considerations. Patients should be monitored regularly for potential complications.

  • Baseline and periodic cardiac assessment (ECG, heart rate).
  • Liver function tests before and during therapy.
  • Ophthalmologic examination for macular edema.
  • Screening for active infections, especially varicella‑zoster.
  • Vaccination status review; live vaccines are contraindicated during treatment.
  • Pregnancy planning discussion, as safety data are limited.

Avoid Interactions

Golpimec can interact with other medicines, affecting its safety or effectiveness. Some combinations should be avoided, while others require careful monitoring.

Avoid

  • Strong CYP4F2 inhibitors (e.g., fluconazole) that may increase fingolimod exposure.
  • Live vaccines during treatment.
  • Concurrent use with other immunosuppressants that markedly increase infection risk.

Use with caution

  • Beta‑blockers or calcium‑channel blockers (may affect heart rate).
  • Antiplatelet or anticoagulant agents (potential bleeding risk).
  • Drugs that prolong QT interval.
  • Vaccines containing inactivated antigens (monitor immune response).

Frequently Asked Questions

Golpimec contains the active ingredient fingolimod, a sphingosine‑1‑phosphate receptor modulator.

Golpimec is indicated for relapsing forms of multiple sclerosis, including relapsing‑remitting and active secondary progressive disease.

Golpimec is taken orally as a prescription medication.

Common side effects include headache, diarrhea, upper respiratory tract infection, elevated liver enzymes, fatigue, and nasopharyngitis.

Serious reactions such as severe infections (e.g., herpes zoster), cardiac conduction problems, macular edema, liver injury, or signs of progressive multifocal leukoencephalopathy should be reported promptly.

Yes, a baseline ECG and heart‑rate assessment are recommended before initiating therapy and after the first dose.

The pregnancy safety category for Golpimec is unknown; women should discuss family planning with their healthcare provider before starting treatment.

Live vaccines are contraindicated during treatment with Golpimec because of its immunomodulatory effects.

Regular monitoring of liver function tests, complete blood count, and ophthalmologic examinations for macular edema is advised.

Golpimec may interact with other immunosuppressants and certain CYP4F2 inhibitors; clinicians should evaluate potential drug‑drug interactions before co‑prescribing.

Fingolimod selectively modulates sphingosine‑1‑phosphate receptors, preventing lymphocytes from leaving lymph nodes, which reduces their presence in peripheral blood and limits inflammatory activity in the central nervous system.

Golpimec is currently marketed as an oral formulation; no other dosage forms or strengths have been reported.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fingolimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT